New foam for Kids' psoriasis shows early promise
NCT ID NCT07340216
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a medicated foam called ARQ-154 (roflumilast) in 22 children aged 2 to 12 with scalp and body psoriasis. The goal was to see how much of the drug enters the bloodstream and whether it is safe. Researchers monitored side effects and skin reactions over two weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Roflumilast foam 0.3%
What this could lead to
If it works, this could provide a new topical treatment option for children with psoriasis, potentially easing symptoms like scaling and itching.
What could go wrong
This is a very early Phase 1 study with only 22 children, so it is mainly checking safety and drug levels, not whether it works well. Side effects or lack of effectiveness may still arise.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arcutis Clinical Study Site 104
Arlington, Texas, 76011, United States
-
Arcutis Clinical Study Site 105
West Lafayette, Indiana, 47906, United States
-
Arcutis Clinical Study Site 106
Bryant, Arkansas, 72022, United States
-
Arcutis Clinical Study Site 107
Miami Lakes, Florida, 33014, United States
-
Arcutis Clinical Study Site 108
Meridian, Idaho, 83646, United States